Assessing abuse liability in clinical trials

被引:25
作者
Brady, KT
Lydiard, RB
Brady, JV
机构
[1] Med Univ S Carolina, Ralph H Johnson Med Ctr, Dept Psychiat, Charleston, SC 29401 USA
[2] SE Hlth Consultants, Charleston, SC 29407 USA
[3] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21224 USA
关键词
clinical trials; registration-focused trials; abuse liability; discontinuation-emergent symptoms;
D O I
10.1016/S0376-8716(03)00101-7
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
In this article, the use of data collected in registration-focused clinical trials to provide information concerning abuse liability of compounds under development is discussed. Registration-focused trials are limited by the small and select sample chosen for study participation and design constraints. However, most compounds under development are first administered to humans during the conduct of registration-focused trials, so this presents an opportunity to collect potentially important information about the effects of drugs in humans. At present, information concerning subjective effects and symptoms associated with drug discontinuation are not collected systematically. Reports are generally considered as adverse events (AEs) and are recorded on the case report forms (CRFs) in the investigators own language. There is generally no rating of drug "liking". The authors suggest strategies that could be implemented in registration-focused clinical trials to improve the information gathered with regard to subjective effects, abuse liability and discontinuation-emergent symptoms. Importantly, there remains much groundwork to be done in developing and validating appropriate assessment instruments and determining "threshold" levels for concern. Under the best of circumstances, registration-focused clinical trials have limited potential to detect abuse liability because of the small number of patients seen and the exclusion of many subjects who might be particularly vulnerable to the abuse of marketed compounds (i.e. individuals with substance use disorders). In cases where there are reasons to suspect that a drug under development has abuse potential, systematic exploration with a series of studies specifically designed to assess abuse potential must be conducted. (C) 2003 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:S87 / S95
页数:9
相关论文
共 18 条
[1]   Postmarketing surveillance for drug abuse [J].
Arfken, CL ;
Cicero, TJ .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S97-S105
[2]   Principles of drug abuse liability assessment in laboratory animals [J].
Ator, NA ;
Griffiths, RR .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S55-S72
[3]   Guidelines and methodological reviews concerning drug abuse liability assessment [J].
Balster, RL ;
Bigelow, GE .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S13-S40
[4]  
BIGELOW GE, 1980, ARCH GEN PSYCHIAT, V37, P1118
[5]  
BRADY JV, 1984, NATL I DRUG ABUSE RE, V52
[6]  
BRADY KT, IN PRESS AM PSYCHIAT
[7]   A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States [J].
Cicero, TJ ;
Adams, EH ;
Geller, A ;
Inciardi, JA ;
Muñoz, A ;
Schnoll, SH ;
Senay, EC ;
Woody, GE .
DRUG AND ALCOHOL DEPENDENCE, 1999, 57 (01) :7-22
[8]  
Collins JM, 2000, CLIN CANCER RES, V6, P3801
[9]  
DEWIT H, 1986, DRUG ALCOHOL DEPEN, V86, P1625
[10]   Principles of initial experimental drug abuse liability assessment in humans [J].
Griffiths, RR ;
Bigelow, GE ;
Ator, NA .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (03) :S41-S54